Fasinumab Drug Asset Due Diligence Report 2026

This Fasinumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Discontinued

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Fasinumab can convert its Monoclonal antibody profile and NGFB biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Fasinumab (query alias: fasinumab)
Modality / target	Monoclonal antibody; NGFB; NGFB inhibitors
Highest global status	Discontinued
Originator	Regeneron Pharmaceuticals, Inc.
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03691974	Phase 2	Completed	180	Change From Baseline in Peroneal Motor Nerve Conduction Velocity at Week 16
EUCTR2018-001411-71-GB	Phase 2	Prematurely Ended	131	The endpoints of this exploratory study are: • Change and percent change from baseline to week 16 in synovial fluid biomarkers reflecting bone turnover (procollagen type 1 N-terminal peptide [P1NP] and type-I collagen degraded by matrix metalloproteinase [C1M]), cartilage turnover (type-II collagen degraded by matrix metalloproteinase [C2M]) and inflammation (type-III collagen degraded by matrix metalloproteinase [C3M]) • Change and percent change from baseline to week 16 in synovial fluid white blood cell (WBC) count • Change and percent change from baseline to week 16 in crystal count/high powered field • Number and percentage of patients at baseline and week 16 with semi-quantitative measure of crystals (ie, no crystals, few crystals, moderate amount of crystals, many crystals) • Change and percent change from baseline to week 16 in intracellular crystal count/high powered field
NCT03949673	Phase 2	Terminated	23	Number of Participants by Degree of Synovial Lymphocytic Inflammation

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to osteoarthritis of the knee or hip

Phase 3; n=1801; evaluation: Positive. Reported fields: Adjudicated arthropathies = 2.6 % ; Adjudicated arthropathies = 9.7 % ; Adjudicated arthropathies = 7.2 %

A Phase 3 Randomized, Double-blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Phase 3; n=5331; evaluation: not stated. Reported fields: Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) = 1055 Participants ; -; -

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Phase 2; n=180; evaluation: not stated. Reported fields: Change From Baseline in Peroneal Motor Nerve Conduction Velocity at Week 16(Least Squares Mean): Least Square (LS) Mean Difference = 0.4(95% CI, -0.55 to 1.32), P-Value = 0.4192; Change From Baseline in Peroneal Motor Nerve Conduction Velocity at Week 16(Least Squares Mean) = -0.2 m/sec (Standard Error, 0.46); Change From Baseline in Peroneal Motor Nerve Conduction Velocity at Week 16(Least Squares Mean) = 0.2 m/sec (Standard Error, 0.42)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Fasinumab addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2007-11-29	Regeneron initiates major global collaboration with Sanofi-aventis to develop and commercialize fully-human therapeutic antibodies	Discovery	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION